Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma
Status:
Not yet recruiting
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
This will be a prospective, open label, single center, phase I lead-in study of 10 patients
to a single arm phase-II study of 37 additional patients to assess the effectiveness of
pembrolizumab and lenvatinib combination therapy for recurrent glioblastoma (rGBM) patients
wearing TTFields electrodes.